Curasight A/S appointed Hanne Damgaard Jensen as new Chief Development Officer. Curasight intends to expand and accelerate its clinical programs and is strengthening the organisation with Hanne Damgaard Jensen who will take on the position as Chief Development Officer (CDO) from 1 January 2022. Hanne will be responsible for all Drug Development and Regulatory Affairs activities in the Company. Hanne holds a Master of Science degree in Pharmaceutical Sciences from the University of Copenhagen and an MBA from Copenhagen Business School. She has previously held several managerial positions across different development and regulatory disciplines and positions within clinical oncology development in both smaller and larger pharma companies. Thus, Hanne was the 4th employee in Genmab back in 1999 and with increasing managerial responsibilities over 7 years, building the organization, Hanne was responsible for the drug development project organization with 80 employees in 2007. In addition to positions held in Genmab, Novo Nordisk, Santaris Pharma, Iolab (Johnson & Johnson) and Azanta, Hanne is also the CEO and founder of ROS Therapeutics. Together, her track-record highlights her valuable knowledge and experience in relation to the strategy that Curasight is in the process of rolling out.